GlaxoSmithKline PLC (GSK.L)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2015||Non-Executive Chairman of the Board|
|49||2017||Chief Executive Officer, Executive Director|
|55||2019||Chief Financial Officer, Executive Director|
|2018||President - Vaccines|
|50||2016||Chief Executive Officer - GSK Consumer Healthcare|
- Study shows major real-world impact of cervical cancer vaccines
- FTSE 100 steady, Sino-U.S. trade talks back in focus
- UPDATE 2-Britain's FTSE 100 steady, Sino-U.S. trade talks back in focus
- BRIEF-Valneva Announces Mutual Agreement With GSK To End Strategic Alliance Agreement
- GSK offers concessions to address EU concerns over Pfizer deal
- How safe is GlaxoSmithKline plc’s dividend?
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- Which of these Neil Woodford dividend stocks should you buy today?
- 3 blue chip bargains you can't afford to miss!
- Are these 3 top stocks still mighty income machines?
- Now is the perfect time to buy these 3 healthcare stocks!